3 Clinical psychopharmacology3.2 Pharmacokinetics
3.2.3 Pharmacokinetically mediated
5 min read2 figures
Written by Resident Doctor Committee · Published
Pharmacokinetic and pharmacodynamic interactions
A pharmacokinetic interaction changes how much of a drug reaches its target by altering absorption, distribution, metabolism or excretion.
A pharmacodynamic interaction changes the response at an unchanged concentration.
How much an interaction matters depends on how much the affected pathway contributes, the drug's therapeutic index, and the timing: inhibition acts quickly, while induction develops and resolves over weeks.
Absorption
Chelation happens when a polyvalent cation binds a drug in the gut into a complex that cannot be absorbed; metal ions bind tetracyclines and quinolones this way.
Separating the doses helps binding interactions but does not prevent effects from altered gut pH, motility or intestinal enzymes, such as grapefruit juice inhibiting intestinal CYP3A4.
Distribution and protein binding
Displacement from plasma protein binding raises the free fraction of a highly bound drug, as when clozapine displaces warfarin from albumin and potentiates anticoagulation.
The measured total level can then fall, so raising the dose of valproate or phenytoin to correct a low total level risks toxicity.
Enzyme inhibition and induction
Feature | Inhibition | Induction |
|---|---|---|
Mechanism | Enzyme activity falls | Enzyme synthesis rises |
Effect on substrate | Clearance falls, level rises | Clearance rises, level falls |
Timing | Starts quickly; steady state takes 4 to 5 half-lives | Onset and reversal take 1 to 2 weeks or longer |
Withdrawal | Stopping it lowers levels | Stopping it raises levels |
Mechanism-based inhibitors, such as clarithromycin and ritonavir at the cytochrome P450 (CYP) enzyme CYP3A4, inactivate the enzyme until it is replaced, so their effect outlasts withdrawal.
Inducers include carbamazepine, phenytoin, phenobarbital, rifampicin, St John's wort and tobacco smoke; valproate is not an inducer.
Clozapine
Clozapine is cleared mainly by CYP1A2, with CYP3A4 a minor route, so CYP1A2 inducers, inhibitors and competing substrates drive its plasma level.
Factor | Mechanism | Effect on clozapine |
|---|---|---|
Tobacco smoking | Hydrocarbons in smoke induce CYP1A2 | Level falls; smokers need higher doses |
Stopping smoking | Induction wears off | Level rises within days |
Caffeine, heavy intake | Competes for CYP1A2 | Level rises |
Fluvoxamine | Potent CYP1A2 inhibitor | Level rises several-fold within days |
Omeprazole | Induces CYP1A2 | Level falls; psychotic relapse can follow weeks later |
Significant inflammation or infection | Suppresses CYP1A2 | Level rises |
Fluoxetine, paroxetine | Potent CYP2D6 inhibitors | Level rises, with dose-related effects such as seizures |
Stopping smoking on an unchanged dose, for example on a smoke-free admission, leads to clozapine toxicity unless the dose is reduced; olanzapine levels rise the same way.
Nicotine is not the inducer, so nicotine replacement and vaping do not maintain the induction.
Other antidepressants have a mild or negligible effect on clozapine levels.
Recovery from infection or restarting smoking lowers clozapine levels again.
Other cytochrome P450 interactions
Affected drug | Pathway | Interacting drug | Result |
|---|---|---|---|
Agomelatine | Almost entirely CYP1A2 | Ciprofloxacin, fluvoxamine | Levels multiply; combination contraindicated |
Nortriptyline | CYP2D6 | Fluoxetine | Levels stay high for weeks after fluoxetine stops |
Trazodone | Mainly CYP3A4 | Ritonavir | Exposure more than doubles; start at a low dose |
Guanfacine | CYP3A4/5 | Moderate or strong CYP3A4 inhibitor | More sedation and hypotension |
Tricyclics with haloperidol or phenothiazines | CYP2D6 | Each other | Each raises the other's level |
Norfluoxetine, fluoxetine's active metabolite, has a half-life of 1 to 2 weeks, which is why its CYP2D6 inhibition persists.
Trazodone at raised exposure causes postural hypotension and fainting through alpha-1 blockade.
Fluoxetine and paroxetine can also raise risperidone, aripiprazole and atomoxetine levels through CYP2D6.
CYP2D6 inhibition reduces activation of prodrugs, so codeine gives less morphine and paroxetine is avoided with tamoxifen.
Anticonvulsants
Valproate inhibits lamotrigine glucuronidation, roughly doubling its level and raising the risk of toxicity and rash, so lamotrigine starts at half the dose and is titrated more slowly.
Carbamazepine and phenytoin induce lamotrigine metabolism and lower its level.
Enzyme inducers, carbamazepine among them, speed valproate clearance and lower its level, while enzyme inhibitors raise it.
Carbamazepine lowers most co-prescribed anticonvulsants but can raise phenytoin, sometimes to toxic levels.
An antipsychotic dose raised to compensate for carbamazepine can become toxic when carbamazepine stops.
Contraception and warfarin
CYP3A4 inducers, including St John's wort, carbamazepine and topiramate, speed clearance of ethinylestradiol and progestogen and cause combined oral contraceptive failure.
Non-inducing drugs, such as renally excreted anticonvulsants and valproate, leave the pill effective.
Implants are also affected by induction, but intrauterine contraception and depot medroxyprogesterone are not.
St John's wort induces CYP3A4, CYP2C9, CYP2C19 and P-glycoprotein through hyperforin, lowering warfarin levels, the international normalised ratio and anticoagulant effect, so it is avoided with warfarin.
Renal elimination and lithium
Two drugs sharing an active tubular transporter compete at the proximal tubule, so secretion and renal clearance of both fall and plasma levels rise; probenecid reduces penicillin secretion this way.
Lithium is filtered and reabsorbed alongside sodium without metabolism, so tobacco smoke induction of hepatic enzymes leaves its level unchanged, unlike psychotropics that depend partly on CYP1A2.
Drug | Mechanism | Effect on lithium |
|---|---|---|
Thiazide and thiazide-like diuretics | Sodium loss drives compensatory proximal reabsorption of sodium and lithium | Level rises; toxicity on an unchanged dose |
Angiotensin-converting enzyme (ACE) inhibitors | Lower aldosterone, filtration and thirst, and cause sodium loss, so proximal reabsorption rises | Level rises |
Non-steroidal anti-inflammatory drugs (NSAIDs), selective or not | Block renal prostaglandins, lowering renal blood flow and filtration and raising proximal reabsorption of sodium and lithium | Level rises |
Loop diuretics, angiotensin receptor blockers | Reduce lithium clearance | Level rises |
Xanthines (theophylline, caffeine), carbonic anhydrase inhibitors | Reduce proximal reabsorption or raise filtration | Level falls |
Vomiting, diarrhoea, fever, sweating, dehydration and low salt intake also raise lithium levels.
Toxicity presents with coarse tremor, vomiting, ataxia, confusion or seizures; withhold lithium and check an urgent level, renal function and electrolytes.